Scientific breakthroughs make the front page for a day. Then they vanish. By the next morning, you're reading about something else entirely.
But these discoveries don't end when the press coverage does. They unfold over months and years: clinical trials continue, telescopes gather data, gene therapies show long-term results, and regulatory decisions shape whether a discovery ever reaches the people who need it.
These six stories are still unfolding right now. Each one could reshape medicine, agriculture, or our understanding of the universe. And each one is being tracked on Pingmer.
This is the first post in our Stories Worth Tracking series, where we highlight developing stories across science, policy, technology, and more — stories that deserve your attention beyond the initial headline. See also our guide to microchip research worth tracking for semiconductor developments that will shape technology for decades.
1. Personalized CRISPR Gene Therapy Saves an Infant's Life
In February 2025, a baby named KJ Muldoon became the first person to receive a personalized CRISPR base-editing treatment. He was born with CPS1 deficiency — a rare metabolic disorder that causes dangerous ammonia buildup in the blood. Without treatment, it's often fatal.
Researchers at Children's Hospital of Philadelphia and Penn Medicine developed a custom gene therapy specifically for KJ in just six months. He received three infusions between February and April 2025. The results, published in the New England Journal of Medicine, showed increased protein tolerance and no adverse effects.
Why it matters: This wasn't a one-size-fits-all drug trial. It was a therapy designed for one patient's specific mutation. If the approach scales, personalized gene editing could become a treatment pathway for thousands of rare diseases that currently have no cure.
What to watch: KJ's long-term health outcomes, whether additional patients receive similar personalized therapies, and how regulatory frameworks adapt to treatments designed for a single person.
2. A New Antibiotic for Drug-Resistant Gonorrhea
The WHO has called antibiotic resistance one of the top global health threats. Gonorrhea is a prime example — strains resistant to every recommended antibiotic have been spreading for years. In December 2025, the FDA approved NUZOLVENCE (zoliflodacin), a first-in-class oral antibiotic that works against drug-resistant gonorrhea with a single dose.
The journey from concept to approval spanned over a decade, with Phase 2 results published in the New England Journal of Medicine in 2018 and Phase 3 results in The Lancet in 2025. No injections required. No complex multi-drug regimens.
Why it matters: Drug-resistant infections kill over 1.2 million people annually, according to The Lancet. Each new effective antibiotic is a critical line of defense. Zoliflodacin's approval represents both a specific treatment breakthrough and proof that the antibiotic development pipeline can still produce results.
What to watch: U.S. market launch expected in 2026, international regulatory submissions in South Africa and Thailand, real-world resistance patterns, and whether the single-dose oral format improves treatment adherence.
3. Cancer Cells Are Stealing Energy from Your Neurons
In June 2025, researchers published a landmark study in Nature revealing that cancer cells can physically extract mitochondria — the energy-producing components of cells — directly from nearby nerve cells. They do this through structures called "tunneling nanotubes," essentially building tiny bridges to steal a neuron's power supply.
The findings apply to multiple cancer types. Glioblastoma cells extract mitochondria from brain support cells called astrocytes. Breast cancer cells target neuronal mitochondria specifically to fuel metastatic spread.
Why it matters: This fundamentally changes how we understand tumor metabolism. If cancers are literally hijacking neurons for energy, then targeting that transfer mechanism could open an entirely new class of therapies. Researchers in Canada have already identified an existing HIV medication that may be repurposable to disrupt this process.
What to watch: Drug repurposing trials targeting mitochondrial transfer, whether this mechanism extends to other cancer types, and the development of therapies that block tunneling nanotubes.
Start tracking science stories →
4. The World's Most Powerful Astronomy Camera Is About to Turn On
The Vera C. Rubin Observatory in Chile houses the Simonyi Survey Telescope with a 3.2-gigapixel camera — the largest digital camera ever built for astronomy. After over two decades of development, the observatory completed construction in October 2025 and is now in final preparations for its primary mission: the Legacy Survey of Space and Time (LSST).
The LSST will photograph the entire visible sky every few nights for ten years. That's tens of billions of objects cataloged, tracked, and monitored for changes. The first peer-reviewed publication from pre-survey observations was released in January 2026.
Why it matters: This observatory is expected to discover more objects in its first year than all previous astronomical surveys combined. It could find thousands of near-Earth asteroids, map dark matter distribution across the universe, and detect transient events like supernovae almost as they happen. The data will be publicly available, democratizing astronomical research on a scale never attempted before.
What to watch: The start date for full survey operations (expected early 2026), first major discoveries, and how the astronomical community handles the unprecedented flood of data.
5. Pig Organs in Human Patients
The idea of transplanting animal organs into humans has existed for decades. In 2025, it became clinical reality. The FDA approved the first multi-patient clinical trials for gene-edited pig kidney transplants in February 2025, and by November, NYU Langone Health launched its EXPAND clinical trial.
The timeline of milestones is remarkable: the first gene-edited pig kidney transplant into a deceased recipient in September 2021, the first pig heart into a living patient in January 2022, and by late 2024, patients like Towana Looney being discharged from the hospital with functioning pig kidneys. China performed its first pig lung transplant in May 2024.
Why it matters: Over 100,000 Americans are on the organ transplant waiting list. Seventeen people die every day waiting, according to the U.S. Health Resources and Services Administration. If xenotransplantation works at scale, it could effectively eliminate the organ shortage — pigs can be bred to meet demand in ways human donors never could.
What to watch: Results from the EXPAND trial, long-term outcomes for living recipients, whether regulatory agencies approve expanded use, and developments in pig heart and lung transplants.
6. A Gene That Makes Rice Survive Extreme Heat
Researchers at Huazhong Agricultural University discovered a natural gene variant called QT12 that allows rice to withstand extreme heat while maintaining — and even boosting — yield. In field trials, QT12 increased rice yields by 31-93% under high-temperature conditions and produced almost 80% more grain under heat stress.
The study, published in Cell in May 2025, described QT12 as a natural "on-off system" that protects rice grains from heat damage. The gene variant exists naturally in some rice varieties — it's not a synthetic modification. And it may be applicable to other crops beyond rice.
Why it matters: Rice feeds roughly half of humanity. Climate change is pushing temperatures beyond what current crop varieties can handle. A natural gene variant that dramatically improves heat tolerance isn't just an agricultural breakthrough — it's a food security development that could affect billions of people. Research teams are already working with agricultural companies to integrate QT12 into commercial breeding programs.
What to watch: Commercial breeding program results, whether QT12 transfers successfully to other crops like wheat and corn, adoption rates in heat-affected agricultural regions, and long-term field performance data.
Why Scientific Breakthroughs Need Tracking
Scientific breakthroughs follow a predictable media pattern: a big announcement, a burst of coverage, then silence. But the real story is what happens after the headline.
KJ Muldoon's gene therapy could succeed long-term or encounter unforeseen complications. Zoliflodacin could transform STI treatment or face resistance of its own. The Rubin Observatory could rewrite our understanding of the cosmos. Pig organs could end the transplant waiting list — or hit unexpected immunological walls.
These aren't stories with endings. They're stories in the middle. The kind of stories where you read the headline and think, "I want to know how this turns out." This is what we call the 72-hour forgetting problem — you see the headline, you care, and then three days later it's gone from your mind entirely.
If you've ever found yourself searching "whatever happened to that gene therapy baby" or "did they ever launch that telescope" — that's the gap story tracking fills.
Track Science Stories That Matter to You
Pingmer monitors each of these stories continuously, building a timeline and notifying you when something actually changes. No keyword noise. No manual checking. Just the facts, as they develop.
You can explore these threads and more on the Pingmer public timeline, or sign up free to start tracking up to 5 stories of your own.
The breakthroughs aren't over. They're just getting started.
Frequently Asked Questions
How does Pingmer track scientific breakthroughs?
Pingmer uses AI to understand the context of a story — not just keyword matches. When you submit a URL about a scientific development, the AI reads the article, identifies what the story is about, and then continuously scans for genuine developments: new study results, regulatory decisions, clinical trial outcomes. You get notified when the facts actually change, not every time someone mentions a keyword. Learn more about how story tracking works.
Can I track stories from specific scientific journals?
Yes. You can submit a URL from any source — journal articles from Nature, The Lancet, or Cell, news coverage from science journalists, press releases from research institutions, or even a Wikipedia article about an ongoing study. Pingmer's AI extracts the core story and monitors for developments across all available sources.
How is this different from Google Scholar alerts?
Google Scholar alerts notify you about new papers matching keywords. Pingmer tracks the story, not the keywords. For example, if you're tracking the KJ Muldoon gene therapy case, Pingmer monitors for clinical updates, regulatory decisions, and new patient treatments — not just papers that mention "CRISPR" or "CPS1." This is the same distinction that separates Pingmer from Google Alerts more broadly.
Is Pingmer free?
Pingmer's free plan lets you track up to 5 stories. If you're following several scientific breakthroughs and want to monitor more, the paid plan covers up to 25 stories for $8/month. See pricing for details.
What other types of stories can I track?
Pingmer works for any developing story — not just science. People use it to follow court cases, regulatory changes, missing person cases, political developments, mergers, and more. If it's a story that unfolds over time, Pingmer can track it. Check out our guide on how to track news stories for ideas.